What Pantho 7.5% Treats: Main Uses and Benefits

The therapeutic application of Pantho 7.5% (Dexpanthenol) is relevant in contexts involving heightened systemic burden and symptoms related to inflammatory or irritative states. The medication is commonly used across domains where additional symptomatic support is needed for either epithelial integrity or impaired gut function.

---

Supportive Relief for Skin and Functional Integrity

Pantho 7.5% is commonly used to provide symptomatic relief for conditions involving a compromised skin barrier and minor damage. This helps address symptom clusters that may become intense or disruptive, such as dryness, scaling, and the accompanying redness and itching in conditions like xerosis, minor burns, and diaper dermatitis. The preparation is also relevant for easing symptoms linked to organ-specific functional stress, such as dermatitis associated with radiation therapy or post-operative reduced functional bowel movement (like abdominal distention and difficulty passing flatus). By supporting the relief of dryness and functional stability of the skin barrier, the medication contributes to easing discomfort during symptomatic periods.

---

Specialized Management

The medication may be part of symptomatic management in highly specific contexts, such as easing symptoms linked to corneal injuries or addressing groups of symptoms that may appear due to Vitamin B5 deficiency in patients receiving specialized nutrition. Its use may assist with maintaining functional stability and contributes to improved comfort during symptomatic phases.

---

Quick Fact: Relief for Post-Surgical Gut Symptoms

Official Population Eligibility for Pantho 7.5% (Dexpanthenol)

Eligibility for Pantho 7.5% is strictly governed by regulatory status, with specific rules differentiating between the injectable (systemic) and topical preparations. All patients with a documented hypersensitivity to dexpanthenol or any component of the formulation are absolutely contraindicated from using the medicine.

Contraindications and Restrictions

Population Group / Condition	Formulation Type	Regulatory Status
Hypersensitivity to ingredients	All	Contraindicated
Ileus due to mechanical obstruction	Injectable	Contraindicated
Within one hour of Succinylcholine	Injectable	Contraindicated

Age and Physiological Restrictions

For the injectable (systemic) preparation, safety and effectiveness have not been established in pediatric patients. Use in pregnancy is classified as Category C, meaning it should only be administered if clearly needed. For nursing mothers, it is not known if the drug is excreted in human milk, and caution is advised. Topical preparations are generally considered permissible during pregnancy and lactation. Standard use is established for adults with specific indications, and for adults and children requiring topical skin protection.

The officially documented interaction profile for Pantho 7.5% is delineated based on the product's specific route of administration, creating distinct profiles for the systemic (injectable) and topical preparations.

Interactions Specific to Systemic Use

For the topical formulation, regulatory sources consistently state that no drug interactions have been reported. This absence is based on the limited systemic exposure and localized action of the creams and ointments.

The interaction profile for the systemic (injectable) preparation is centered on its pharmacodynamic activity. Co-administration with the neuromuscular blocking agent Succinylcholine is officially documented as potentially resulting in the prolongation of Succinylcholine's effects. Consequently, a mandatory timing restriction is enforced: Dexpanthenol Injection must not be administered within one hour of Succinylcholine.

The official regulatory documents also note reports of rare allergic reactions when the injection is used alongside certain medicinal product classes, including antibiotics, narcotics, or barbiturates. The regulatory labels do not contain information regarding formal interactions with food, alcohol, or herbal products, nor are there officially stated interactions related to drug metabolism via CYP enzymes or transporters.

Pantho 7.5% acts as an acid-activated prodrug, concentrating selectively within the secretory canaliculi of the gastric parietal cells. Here, under the low pH environment, it is converted into its active form, a sulfenamide derivative.

Irreversible Inhibition of Gastric Proton Pump

This active metabolite then forms a covalent bond with specific sulfhydryl groups on the extracellular domain of the H^+/K^+-ATPase enzyme, commonly known as the proton pump. This binding represents a non-competitive, irreversible modification of the enzyme.

Modulation of Acid Secretion Cascade

By inactivating the H^+/K^+-ATPase, the drug prevents the final step of hydrogen ion extrusion into the stomach lumen. This mechanism results in the inhibition of both basal and stimulated gastric acid secretion. This blockade bypasses the diverse signaling pathways (such as those mediated by histamine, gastrin, or acetylcholine) that converge on the pump, leading to a substantial lowering of gastric lumen acidity.

How to Use Pantho 7.5% — Administration Guidelines

Pantho 7.5% (Dexpanthenol) is utilized via two primary administration routes: a parenteral solution for systemic use, and various topical formulations (creams or ointments) for cutaneous application.

---

Parenteral Dosing and Schedule

Systemic use follows an acute, short-term schedule. The standard adult dose for established use is 500 mg (2 mL of the 250 mg/mL solution), which is administered via Intramuscular (IM) injection or as a slow Intravenous (IV) infusion.

• Frequency: The regimen starts with an initial dose, repeated after 2 hours, followed by maintenance doses every 6 hours thereafter, on an as-needed basis.
• Duration Principle: Parenteral use is strictly short-term, continuing only until the acute period requiring systemic support has concluded.
• Preparation Requirement: The IV dose must be mixed with a bulk IV solution (such as Lactated Ringer's or glucose) before administration; it is not permitted for direct, undiluted IV injection. All solutions must be visually inspected for any particulate matter.

---

Topical Application

Topical products are intended for external use only. The application protocol is focused on continuous coverage:

• Application: A thin layer of the cream or ointment is applied to the affected area.
• Frequency: Typically applied once or twice daily, or frequently enough to maintain coverage, such as with each diaper change for applicable products.

The instructions define a comprehensive protocol for this medicine, specifying the required dilution for the IV route and time-bound administration intervals for the parenteral injection, alongside standardized application for topical forms. No explicit numerical dose adjustments for specific populations, such as older adults, are mandated in the administration sections.

Research evidence / Overview of studies for Pantho 7.5%

Evidence for Use in Topical Applications (Skin Barrier and Epithelial Support)

Research exploring the topical use of Dexpanthenol was evaluated in various clinical settings, primarily through Randomized Controlled Trials (RCTs) and Prospective Clinical Studies. These studies often use objective, non-invasive instruments to monitor outcomes linked to inflammatory or irritative states. The research included study groups such as adult volunteers and patients who have undergone minor dermatological or aesthetic procedures—contexts that involve temporary skin disruption.

Studies monitored functional outcomes like Transepidermal Water Loss (TEWL), which researchers used to monitor changes in the skin's barrier function, and changes in skin hydration measured by objective instruments. The findings describe patterns observed in the studies related to changes in skin hydration and TEWL during the observed period. The evidence was categorized as High in studies that focused on instrumental barrier measurements.

Evidence for Use in Systemic Applications (Post-Operative Gut Motility)

Research into the systemic (injectable) use of Dexpanthenol was evaluated in a different clinical context, focusing on outcomes related to systemic or functional imbalance in the gastrointestinal tract. Studies in this area include Older Randomized Controlled Trials and early prospective studies. The research examined Adult Patients who had undergone intestinal or major abdominal surgery.

These studies monitored and examined functional endpoints such as the time interval until a specific marker of gastrointestinal activity was recorded post-operation. Some trials reported patterns related to the time measured until functional bowel markers, such as the time to first flatus, were recorded. The evidence level for this indication is categorized as Moderate.

What Is Still Uncertain About Pantho 7.5% Research

Research highlights what is known—and what is still uncertain—about the available evidence. Follow-up durations were limited in many trials, generally covering only a few days up to a few weeks, meaning long-term effects are not fully established. Data for certain groups remain insufficient, especially for populations such as children or those with specific comorbidities. Comparative evidence is lacking for many formulations. In summary, the research provides context but not individual predictions.

Key Studies & References Efficacy and Safety of Topical Dexpanthenol-Containing Spray and Cream in the Recovery of the Skin Integrity Compared with Petroleum Jelly after Dermatologic Aesthetic Procedures (Comparative Study)

Common questions about Pantho 7.5% (FAQ)

Q: Are there any common over-the-counter drugs, like pain relievers, that I shouldn't take with Pantho 7.5%?

Official drug information documents list documented interactions only with the muscle relaxant Succinylcholine. These documents also note reports of rare allergic reactions when the injection is used alongside certain medicinal product classes, including antibiotics, narcotics, or barbiturates.

Regulatory documents do not specifically list formal interactions with common, non-narcotic over-the-counter (OTC) pain relievers in the current label information.

---

Q: Does this medicine interact with food or alcohol?

According to the official regulatory documents, there is no information available regarding formal interactions between Pantho 7.5% and food or alcohol. The official labels do not contain specific information regarding the consumption of food or alcohol with this medicine.

---

Q: Can I take Pantho 7.5% if I am pregnant or breastfeeding?

The systemic (injectable) form is classified as Pregnancy Category C, which suggests administration should occur only when clinical benefit is deemed to clearly outweigh potential risks. For nursing mothers, it is not known if the drug is passed into human milk, and official caution is advised.

In contrast, the topical cream or ointment preparations are generally considered acceptable for use during both pregnancy and lactation, according to official information.

Storage and Disposal Requirements

The storage and disposal of Pantho 7.5% (Dexpanthenol) must adhere strictly to the conditions documented in official regulatory labeling to ensure product stability and safety.

Storage Conditions

The solution for injection must be stored between 15°C and 30°C (59°F and 86°F). It is prohibited to freeze the solution, and storage below 15°C must be avoided. The medicine must be kept in its original container. Since the injection is for single use only, any unused portion remaining in the container after administration must be immediately discarded. Before use, the solution must be visually inspected; it should be clear and colorless, and must not be used if it appears cloudy or contains precipitate.

Disposal Instructions

All expired or unused medication must be stored out of the sight and reach of children. Disposal should not be conducted via wastewater (sinks or toilets). The preferred method for discarding unused product is through a designated drug take-back program or pharmacy collection point, following local pharmaceutical waste regulations.